Latest Pathology News

Page 5 of 9
Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.
Ada Torres
Ada Torres
26 Aug 2025
Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.
Ada Torres
Ada Torres
26 Aug 2025
Australian Clinical Labs reported robust FY25 financial results with revenue and earnings growth, alongside a strong dividend payout and positive outlook for FY26.
Ada Torres
Ada Torres
26 Aug 2025
Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.
Ada Torres
Ada Torres
26 Aug 2025
Healius Limited reported a 5.7% rise in FY25 revenue driven by pathology growth, while underlying EBIT fell 27% impacted by cyclone disruptions and restructuring. The company advances its pathology strategy and cost savings post-Lumus divestment.
Ada Torres
Ada Torres
21 Aug 2025
Healius reported a 5.7% rise in FY25 revenue with underlying EBIT meeting consensus, buoyed by strong pathology growth and a significant profit from the Lumus Imaging sale. Despite challenges at Agilex Biolabs and a major goodwill impairment, the company targets improved margins by 2027.
Ada Torres
Ada Torres
21 Aug 2025
Sonic Healthcare delivered solid FY2025 results with 8% revenue growth and a 7% rise in net profit, setting the stage for an anticipated 19% earnings per share increase in FY2026.
Ada Torres
Ada Torres
21 Aug 2025
Pro Medicus has delivered a landmark FY25 with soaring revenue and profit, driven by major contract wins and strategic cloud deployments. The company’s expanding North American footprint and AI initiatives set the stage for sustained growth.
Victor Sage
Victor Sage
14 Aug 2025
Charter Hall Social Infrastructure REIT (CQE) reported steady FY25 results with a 15.2 cents per unit distribution and announced a 10.5% increase in guidance for FY26, underpinned by strategic acquisitions and a robust debt refinancing.
Eva Park
Eva Park
11 Aug 2025
Charter Hall Social Infrastructure REIT (CQE) reported solid FY25 results, highlighted by strategic acquisitions, a successful $900 million debt refinancing, and a 10.5% lift in distribution guidance for FY26.
Eva Park
Eva Park
11 Aug 2025
Charter Hall Social Infrastructure REIT has reported a statutory profit of $71 million for FY25, reversing last year’s loss, while advancing its portfolio through key acquisitions and refinancing.
Eva Park
Eva Park
11 Aug 2025
Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.
Ada Torres
Ada Torres
31 July 2025